Please assess the completion status of the following clinical trial:

Trial Title: Topiramate Treatment of Problem Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 65 years, inclusive;~* have an average weekly ethanol consumption of \>=24 standard drinks for men, or \>=18 standard drinks for women;~* be able to read English at the 8th grade or higher level and show no evidence of significant cognitive impairment;~* be willing to nominate an individual who will know the patient's whereabouts in order to facilitate follow up during the study;~* if a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or who are less than two years postmenopausal), must be non-lactating, practicing a reliable method of birth control, and have a negative serum pregnancy test prior to initiation of treatment;~* if applicable, individuals being treated with a single antidepressant that has been stable in dosage for a minimum of four weeks; and~* be willing to provide signed, informed consent to participate in the study (including a willingness to reduce drinking to non-hazardous levels).~Exclusion Criteria:~* a current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation, including direct bilirubin elevations of \>110% or transaminase elevations \>300% normal (We will not exclude patients with hypertension, diabetes mellitus, asthma or other common medical conditions, as long as these are adequately controlled and the patient has an ongoing relationship with a primary-care practitioner);~* a history of nephrolithiasis;~* a history of glaucoma;~* a serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, panic disorder, borderline or antisocial personality disorder, organic mood or mental disorders, eating disorder, or substantial suicide or violence risk) on the basis of history or psychiatric examination;~* a current Diagnostic \& Statistical Manual of Mental Disorders 4th ed (DSM-IV) diagnosis of drug dependence (other than nicotine dependence);~* a current Diagnostic and Statistical Manual of Mental Disorders 4th ed (DSM-IV) diagnosis of alcohol dependence that is clinically moderate or severe;~* a history of hypersensitivity to topiramate;~* currently taking any tricyclic antidepressant (e.g., Adapin (doxepin), Anafranil (clomipramine), Elavil (amitryptyline), Pamelor (nortryptyline), Tofranil (imipramine), Sinequan (doxepin); or~* are considered by the investigators to be an unsuitable candidate for receipt of an investigational drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Total Topiramate Group (Type: ACTIVE_COMPARATOR): topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
- Total Placebo Group (Type: PLACEBO_COMPARATOR): inactive placebo matched in appearance with topiramate capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).